8-K Announcements
6Material company update
Feb 10, 2026·SEC
Material company update
Dec 29, 2025·SEC
Material company update
Nov 5, 2025·SEC
Dynavax is successfully transitioning from pandemic-era adjuvant volatility to a sustainable commercial model anchored by the HEPLISAV-B vaccine franchise. While the company demonstrates improved operating leverage and a robust 84.8% gross margin as of 2025Q3,...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q1 2026Latest Feb 19, 2026 | $0.05-38.5% vs $0.08 | — vs $82M |
Q4 2025 Nov 5, 2025 | $0.21+50.0% vs $0.14 | $95M+18.2% vs $80M |
Q3 2025 Aug 7, 2025 | $0.14+16.7% vs $0.12 | $95M+1.5% vs $94M |
Q2 2025 May 6, 2025 | -$0.77-2666.7% vs $0.03 | $68M-2.0% vs $70M |
Benchmark DVAX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Dynavax Technologies Corporation (DVAX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $15.50 | $1.82B | 77.50 | 19.36% | 9.85% | 4.48% | — | |
| $10.55 | $1.73B | 4.15 | 64.69% | -59.87% | — | — | |
| $3.17 | $227.37M | 9.61 | -31.8% | -5.14% | -1.53% | — | |
| $34.54 | $7.13B | -12.47 | — | -7585.86% | -69.59% | — | |
| $0.47 | $113.74M | 6.71 | 726.68% | 15.88% | 53.04% | — | |
| $8.63 | $9.04B | -22.71 | 668.31% | -598.56% | — | — |
Dynavax Technologies Corporation (DVAX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Dynavax Technologies Corporation (DVAX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Feb 10, 2026·SEC
Dec 29, 2025·SEC
Nov 5, 2025·SEC
Get notified when DVAX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Dynavax Technologies Corporation (DVAX) stock FAQ — growth, dividends, profitability & financials explained
Dynavax Technologies Corporation (DVAX) reported $330.5M in revenue for fiscal year 2024. This represents a 23061% increase from $1.4M in 2002.
Dynavax Technologies Corporation (DVAX) grew revenue by 19.4% over the past year. This is strong growth.
Dynavax Technologies Corporation (DVAX) reported a net loss of $43.4M for fiscal year 2024.
Dynavax Technologies Corporation (DVAX) has a return on equity (ROE) of 4.5%. This is below average, suggesting room for improvement.
Dynavax Technologies Corporation (DVAX) generated $80.5M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.